KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Accumulated Expenses (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Other Accumulated Expenses for 16 consecutive years, with $301000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses changed N/A year-over-year to $301000.0, compared with a TTM value of $301000.0 through Sep 2025, changed N/A, and an annual FY2024 reading of $88000.0, down 78.48% over the prior year.
  • Other Accumulated Expenses was $301000.0 for Q3 2025 at TherapeuticsMD, up from $202000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $59.2 million in Q2 2022 and bottomed at $88000.0 in Q4 2024.
  • Average Other Accumulated Expenses over 5 years is $16.6 million, with a median of $10.1 million recorded in 2021.
  • The sharpest move saw Other Accumulated Expenses soared 580.86% in 2021, then crashed 97.83% in 2023.
  • Year by year, Other Accumulated Expenses stood at $13.3 million in 2021, then soared by 41.3% to $18.8 million in 2022, then plummeted by 97.83% to $409000.0 in 2023, then plummeted by 78.48% to $88000.0 in 2024, then soared by 242.05% to $301000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for TXMD at $301000.0 in Q3 2025, $202000.0 in Q2 2025, and $249000.0 in Q1 2025.